Squawk on the Street Cramer's Morning Take: Eli Lilly 8/13/25
Aug 13, 2025
Cramer signals a bullish stance on a major pharmaceutical company, highlighting insider trading trends that suggest confidence in its rebound. They discuss a recent stock sale, putting a spotlight on NVIDIA's performance and its anticipated price targets. The duo invites listeners to join an investing club for deeper insights and explores educational opportunities for aspiring investors. Tune in for market analysis mixed with actionable investment strategies!
AI Snips
Chapters
Transcript
Episode notes
Insiders Buying After Disappointing Data
- Significant insider buying at Eli Lilly followed disappointing data and signals confidence from top scientists and board members.
- Jim Cramer says insider purchases make him less negative and change his stance on the stock.
Specific Insider Purchases Named
- Jim Cramer recounts specific insider purchases including David Ricks and other executives buying into Eli Lilly.
- He frames those moves as meaningful because insiders could have bought their own stock but chose this company instead.
Change Rating And Consider Buying Back
- Jim Cramer recommends changing the portfolio rating on Eli Lilly from a three to a one and considers buying back shares he previously sold.
- He instructs listeners to watch for buying opportunities and adjust ratings accordingly.